These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 5350345)

  • 1. m-Hydroxyphenylacetic acid formation from L-dopa in man: suppression by neomycin.
    Sandler M; Karoum F; Ruthven CR; Calne DB
    Science; 1969 Dec; 166(3911):1417-8. PubMed ID: 5350345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolism of orally administered L-Dopa in Parkinsonism.
    Calne DB; Karoum F; Ruthven CR; Sandler M
    Br J Pharmacol; 1969 Sep; 37(1):57-68. PubMed ID: 5343357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The excretion of L-dopa metabolites at different hours of the day.
    Aguggini G; Meucci M; Reina G
    Curr Ther Res Clin Exp; 1972 Nov; 14(11):749-57. PubMed ID: 4629113
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolism of dopa in Parkinsonism.
    Sandler M; Karoum F; Ruthven CR
    N Engl J Med; 1969 Dec; 281(25):1429. PubMed ID: 5355467
    [No Abstract]   [Full Text] [Related]  

  • 5. A simple and rapid gas chromatography for determining 3,4-dihydroxyphenylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid in urine from patients with parkinsonism treated with L-3,4-dihydroxyphenylalanine.
    Fukaya J; Imai K; Tamura Z
    Clin Chim Acta; 1971 Jul; 33(2):470-2. PubMed ID: 5119325
    [No Abstract]   [Full Text] [Related]  

  • 6. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
    Marjerrison G; Boulton AA; Rajput AH
    Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451
    [No Abstract]   [Full Text] [Related]  

  • 7. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
    Routh JI; Bannow RE; Fincham RW; Stoll JL
    Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
    [No Abstract]   [Full Text] [Related]  

  • 8. Gut flora and the origin of some urinary aromatic phenolic compounds.
    Goodwin BL; Ruthven CR; Sandler M
    Biochem Pharmacol; 1994 Jun; 47(12):2294-7. PubMed ID: 8031324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excretion of dopa metabolites.
    Kott E; Bornstein B; Eichhorn F
    N Engl J Med; 1971 Feb; 284(7):395. PubMed ID: 5539935
    [No Abstract]   [Full Text] [Related]  

  • 10. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 13. [The effect of alpha-DOPA on the dynamics of urinary excretion of DOPA, catecholamines and their metabolites in healthy subjects and in patients with parkinsonism].
    Matlina ESh; Kandel' EI; Vasil'ev VN; Iadgarov IS; Bol'shakova TD
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(2):205-9. PubMed ID: 4743269
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of a screening test for L-dopa and its metabolites in urine.
    Routh JI; Bannow RE
    Clin Chem; 1971 Sep; 17(9):872-4. PubMed ID: 5571486
    [No Abstract]   [Full Text] [Related]  

  • 15. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 16. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
    Ebinger G; Adriaenssens K
    Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
    [No Abstract]   [Full Text] [Related]  

  • 17. Responses of the urinary excretion of homovanillic acid and of 5-hydroxy-indol-acetic acid to treatment with L-dopa and amantadine.
    Molnár G; Fodor A
    Ther Hung; 1973; 21(1):35-40. PubMed ID: 4792890
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluorometric method for quantitatively estimating urinary dihydroxyphenylethylamine (dopamine), dihydroxyphenylalanine (dopa), and dihydroxyphenylacetic acid (dopac).
    Eichhorn F; Rutenberg A; Kott E
    Clin Chem; 1971 Apr; 17(4):296-300. PubMed ID: 5552365
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic implications in Parkinsonism of m-tyramine formation from L-dopa in man.
    Sandler M; Goodwin BL; Ruthven CR
    Nature; 1971 Feb; 229(5284):414-5. PubMed ID: 4926994
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of L-dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease.
    Boulton AA; Marjerrison GL
    Nature; 1972 Mar; 236(5341):76-8. PubMed ID: 4553458
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.